Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
March 30, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023 Broad...
Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
March 24, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022
March 03, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
February 07, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined five upcoming presentations from across its...
Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
February 03, 2022 19:01 ET
|
Orchard Therapeutics (Europe) Limited
First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated commercially with Libmeldy in Germany and...
Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
January 21, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients ...
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
January 10, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients Initiating U.S. BLA Submission for...
Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th...
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
November 18, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further...
Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021
November 08, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be...